0
Il n'y a pas de produit dans le panier !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > Sonic Hedgehog

Sonic Hedgehog

Brief Information

Name:Sonic Hedgehog Homolog
Target Synonym:HHG-1,Shh unprocessed N-terminal signaling and C-terminal autoprocessing domains,ShhNC,Shh N-terminal processed signaling domains,ShhNp,ShhN,Sonic hedgehog protein,Sonic hedgehog protein N-product,Sonic Hedgehog Signaling Molecule,Sonic Hedgehog (Drosophila) Homolog
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:5
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

Par statut du produit :
Par catégorie de produit :
Par espèce :
Par étiquette :
Par conjugaison :
Cat . Non Espèces Description du produit Structure Pureté Caractéristique
SH7-H5116 Human Human Sonic Hedgehog / Shh (C24II) Protein, premium grade
SH7-H5116-structure
SH7-H5116-sds
SH7-H5229 Human Human Sonic Hedgehog / Shh Protein, His Tag, premium grade
SH7-H5229-structure
SH7-H5229-sds
ACRO Quality

Synonym Name

SHH,HHG-1,Sonic hedgehog,HLP3,HPE3,SMMCI,TPT,TPTPS

Background

Sonic hedgehog protein (SHH) is also known as HHG-1, which belongs to the hedgehog family. SHH is expressed in fetal intestine, liver, lung, and kidney and not expressed in adult tissues. Sonic hedgehog protein can be cleavage into sonic hedgehog protein N-product and sonic hedgehog protein C-product by autolysis. SHH binds to the patched (PTC) receptor, which functions in association with smoothened (SMO), to activate the transcription of target genes. In the absence of SHH, PTC represses the constitutive signaling activity of SMO. Also regulates another target, the gli oncogene. Intercellular signal essential for a variety of patterning events during development. The C-terminal domain displays an autoproteolysis activity and a cholesterol transferase activity. The N-product is the active species in both local and long-range signaling, whereas the C-product has no signaling activity.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
ACC-006 ACC-006 Phase 2 Clinical Jiangsu Aidea Pharmaceutical Co Ltd, China Pharmaceutical University Solid tumours; Carcinoma, Non-Small-Cell Lung Details
Sulforadex SFX-01 Phase 2 Clinical Pharmagra Labs Inc, Evgen Pharma, Lalilab Autistic Disorder; Precancerous Conditions; Subarachnoid Hemorrhage; Ventricular Dysfunction, Left; Lung Neoplasms; Renal Insufficiency, Chronic; Asthma; Parkinson Disease; Hyperplasia; Carcinoma in Situ; Prostatic Neoplasms; Breast Neoplasms; Heart Failure, Diastolic; Kidney Diseases; Neoplasms; Neurodevelopmental Disorders; Heart Diseases; Nasolabial fold wrinkles; Squamous Cell Carcinoma of Head and Neck; Autism Spectrum Disorder; Schizophrenia; Drug-Related Side Effects and Adverse Reactions; Head and Neck Neoplasms Details
NLM-001 NLM-001; TAK-441 Phase 2 Clinical Millennium Pharmaceuticals Inc Carcinoma, Basal Cell; Neoplasms; Carcinoma, Pancreatic Ductal Details
IMP5471-CA Phase 1 Clinical Shanghai Impact Pharmaceutical Co Ltd Hematologic Diseases Details
IMP-5471 IMP-5471; IMP5471 Phase 1 Clinical Shanghai Impact Pharmaceutical Co Ltd Neoplasms Details

This web search service is supported by Google Inc.

totop

Laisser un message